Cancer name Hepatocellular Carcinoma
Cancer Type LIHC
Immunotherapy type Adoptive Cell Therapy
Treatment pMAGE-A1(278-286)
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature hIP-10
Official Symbol PRPF40A
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description The hIP-10 expression levels in the FA-CS-hIP-10 group, FA-CS-hIP-10 and pHIV77–85specific CD8+CTLs, FA-CS-hIP-10 and pMAGE-A1278–286-specific CD8+ CTLs groups were significantly higher thanthat from the corresponding control groups (P<0.0001).
PMID 27301196
Title Folate-Modified Chitosan Nanoparticles Coated Interferon-Inducible Protein-10 Gene Enhance Cytotoxic T Lymphocytes' Responses to Hepatocellular Carcinoma